Run-Long Medtech Secures Nearly RMB 1 Billion Series A+ Follow-on Investment from Xingze Capital to Accelerate Strategic Growth

VCBeat (WeChat: VCBEAT) has learned that Run-Long Medtech, a leading domestic manufacturer in sports medicine, recently announced the completion of its nearly RMB 100 million Series A+ financing round. Gelo Capital served as the exclusive financial advisor for the second consecutive time. This round of financing took place less than six months after the previous one, with existing shareholder Apricot Capital making additional investments. The funds raised will be primarily used to advance product innovation and expand market outreach.

Ruilang Tech is an innovative medical device company focused on the field of sports medicine and strategically positioned in China’s high-end market. Upholding its corporate responsibility of “being patient-needs oriented and aspiring to be a trusted partner for physicians,” the company is committed to building a leading brand in high-end medical devices. Through continuous product innovation, it strives to break international technological monopolies and achieve leapfrog development during the critical window of opportunity for import substitution in the sports medicine device industry.

In 2020, the global healthcare industry was impacted by the COVID-19 pandemic. Amidst these adversities, Reliantech demonstrated resilience and determination, turning challenges into opportunities. By advancing in tandem with other leading enterprises in the industry, Reliantech drove the growth of the sports medicine segment within orthopedics, achieving sustained rapid growth despite the unfavorable market conditions. As we welcome the Year of the Ox, Reliantech is poised to reach new heights of development, propelled by a new round of investment.

Ruilang Tech has always adhered to the principles of professionalism and innovation. By leveraging an authoritative team of experts, professional management talent, an advanced R&D system, and high-quality channel resources, while also harnessing capital strength to increase investment in product development and marketing, the company has achieved remarkable success. Since the beginning of 2021, Ruilang Tech has rapidly obtained registration certificates for four products, including the "plasma radiofrequency ablation probe." To date, it holds more than ten NMPA registration certificates, further enriching its product portfolio. The acquisition of the registration certificate for the plasma radiofrequency ablation probe signifies that Ruilang Tech has completed its product layout in the two major fields of shaver blades and low-temperature plasma radiofrequency, achieving comprehensive coverage of consumables for arthroscopic debridement procedures. Products in this segment account for 25% of the overall sports medicine consumables market. It is the most common and highest-demand segment in sports medicine, yet domestic products have historically failed to meet clinical needs in terms of performance and quality. Through the market expansion driven by these two flagship products, Ruilang Tech has established a significant presence in the sports medicine sector, built a premium domestic brand image, and achieved rapid growth in market share.

Ruilang Tech boasts a sales team with extensive industry experience and strong execution capabilities, having established a sales network covering more than 30 provinces and regions across China. Leveraging high-performance products, a solid brand foundation, and resource advantages, the company has achieved rapid growth in sales performance, with average monthly sales in 2021 reaching three times the level of the same period in the previous year. Looking ahead, Ruilang Tech will further leverage its resources in industry-academia-research collaboration to drive valuable local innovation. By integrating activities such as academic exchanges and basic education training, the company will vigorously promote its new products to the market, expanding product accessibility to meet the needs of a broader population and benefiting public welfare.

Commenting on the success of this funding round, Mr. Wang Zhongran expressed his gratitude to Apricot Capital for their trust, and to all friends from various sectors of society who have consistently paid attention to and supported Reliantec. Reliantec will take this as motivation to continue dedicating itself wholeheartedly to the field of sports medicine, providing high-quality products to physicians and helping patients overcome illness and pain.

As the sole investor in this funding round, Qiang Jing, Partner at Apricot Capital, stated that Relantech is a company that perfectly aligns with Apricot’s investment philosophy. It not only possesses the essential qualities of an outstanding medical technology enterprise but also demonstrates the social responsibility to serve doctors and patients while advancing the field of sports medicine. Qiang expressed confidence that, following this round of financing, Relantech will further optimize its operations, consolidate its market position, and enhance its influence and industry standing. Apricot Capital remains committed to driving the mutual growth of Relantech and the broader sports medicine industry.

Apricot Capital, established in 2015, derives its name from the aspiration to integrate resources across the broader health industry through capital investment, thereby driving sector development and benefiting humanity. Currently, Apricot Capital manages nearly RMB 4 billion in assets. Its investment team comprises more than 20 professionals and advisors with extensive experience in healthcare and medical investments worldwide, boasting diverse expertise in life sciences, pharmaceuticals, finance, and law.

Apricot Capital has always adhered to its mission of promoting the innovation and growth of Chinese enterprises and driving the progress and development of social industries. Leveraging its investment team’s extensive industry experience, global resource network, and outstanding reputation in the field, Apricot Capital spares no effort in helping entrepreneurs realize their startup dreams.